Sasol Ltd. ADS (SSL) Financials Nov 17, 2014, 4:11
Sasol Ltd. ADS (SSL) Financials Nov 17, 2014, 4:11 p.m.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Sasol Ltd. ADS
Fiscal year is July-June. All values ZAR millions. 2010 2011 2012 2013 2014 5-year trend
Sales/Revenue 122.26B 142.44B 169.45B 169.89B 202.68B
Cost of Goods Sold (COGS) incl. D&A 79.18B 90.75B 111.32B 111.58B 131.91B
COGS excluding D&A 72.47B 83.35B 101.67B 100.46B 118.4B
Depreciation & Amortization Expense 6.71B 7.4B 9.65B 11.12B 13.52B
Depreciation 6.51B 7.17B 9.42B 10.91B 13.2B
Amortization of Intangibles 203M 235M 229M 209M 317M
Gross Income 43.07B 51.68B 58.13B 58.31B 70.77B
2010 2011 2012 2013 2014 5-year trend
SG&A Expense 15.95B 18.29B 19.11B 17.68B 19.68B
Research & Development 908M 1.01B 1.26B 1.28B 1.39B
Other SG&A 15.04B 17.29B 17.85B 16.4B 18.29B
Other Operating Expense 3.04B 3.45B 2.29B 3.78B 5.86B
Unusual Expense - (83M) 1.78B 483M 4.77B
EBIT after Unusual Expense - 83M (1.78B) (483M) (4.77B)
Non Operating Income/Expense (759M) (161M) 1.7B 2.44B 1.25B
Non-Operating Interest Income 1.3B 951M 774M 645M 1.18B
Equity in Affiliates (Pretax) - - - - -
Interest Expense 1.48B 1.69B 1.9B 1.81B 1.93B
Gross Interest Expense 1.54B 1.73B 1.92B 2.11B 2.46B
Interest Capitalized 58M 43M 24M 300M 530M
Pretax Income 23.16B 29.12B 35.52B 37.64B 40.97B
Income Tax 6.99B 9.2B 11.75B 12.6B 14.7B
Income Tax - Current Domestic 4.88B 6.01B 8.41B 9.36B 10.8B
Income Tax - Current Foreign 726M 1.19B 1.86B 1.98B 2.13B
Income Tax - Deferred Domestic 1.11B 1.49B 1.71B 1.28B 1.26B
Income Tax - Deferred Foreign 278M 507M (232M) (20M) 511M
Income Tax Credits 0 0 0 0 0
Equity in Affiliates 217M 292M 479M 2.07B 4.14B
Other After Tax Income (Expense) 0 0 0 0 0
Consolidated Net Income 16.39B 20.22B 24.26B 27.11B 30.42B
Minority Interest Expense 446M 426M 674M 837M 837M
Net Income 15.94B 19.79B 23.58B 26.27B 29.58B
Extraordinaries & Discontinued Operations 0 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg 0 0 0 0 0
Discontinued Operations - 0 0 0 0
Net Income After Extraordinaries 15.94B 19.79B 23.58B 26.27B 29.58B
Preferred Dividends 0 0 0 0 0
Net Income Available to Common 15.94B 19.79B 23.58B 26.27B 29.58B
EPS (Basic) 26.68 32.97 39.10 43.38 48.57
Basic Shares Outstanding 597.6M 600.4M 603.2M 605.7M 609M
EPS (Diluted) 25.90 32.85 38.95 43.30 48.27
Diluted Shares Outstanding 615.5M 614.5M 616.2M 606.8M 620.8M
EBITDA 30.8B 37.34B 46.38B 47.97B 58.75B
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Navigating the Legal Storm with Honeywell Look, investors never have it easy, and when lawsuits start flying like today's news about Honeywell Aerospace, you better have your wits about you. Now here comes Kahn Swick & Foti, LLC, ringing the alarm bells. Any holders of Honeywell Aerospace stocks between late June and early September of '26 are squarely in the spotlight....
Continue Reading
PCS Wireless Dives Deeper into Japan's Reuse Market Never thought I'd live to see recycling grabbing headlines, but here we are. PCS Wireless just made a bold move in Japan, aiming to turbocharge its reuse game. They've thrown a hat in the ring with ReNet Japan Group Co., Ltd. (TSE: 3556), splashing cash to snatch up a hefty 10.36% of the company's voting rights. This...
Continue Reading
Rollin' Down the Road of Excellence In the world of healthcare logistics, Medline's MedTrans team isn't just steering trucks—they're steering safety culture and supply chain efficiency. This October, they wrapped up their fourth annual National Truck Rodeo in Mundelein, Illinois. And let me tell you, it was more than just a fancy event. It was about celebrating the real...
Continue Reading
Interest Rates Climb, CLO Metrics Hold Firm Buckle up, folks. As interest rates drift higher like a stubborn balloon, investors are scouring the landscape for any sign of a shaky foundation. Well, here's a bit of solace in the storm: Egan-Jones, the credit rating powerhouse, has released their latest musings on the collateralized loan obligation (CLO) market...
Continue Reading
A Dark Day in Jordan It's a gut punch, hearing news of yet another brutal attack targeting the Christian community in Jordan's Karak province. This act of terror isn't just a regional dagger—it cuts deep into the fabric of shared humanity. On Friday, the tranquil air of a sacred gathering was shattered, leaving behind grief and a call to action for those who refuse to...
Continue Reading
Nashville Becomes a Hotspot for Podcasters Amidst the strumming guitars and honky-tonk vibes of Nashville, Tennessee transformed into the epicenter of podcasting innovation thanks to Rebel Audio's inaugural summit, POD U. Here we had big names like Mike 'Big Mike' Majlak rubbing shoulders with sports experts and media moguls—a true concoction of voices shaping the...
Continue Reading
A Juicy Rivalry with Sweet and Savory Stakes You ever catch yourself watching state pride turn into a marketing showdown? That's what's cookin' with Wisconsin's Johnsonville and Florida's Natural, and believe me, this isn't just about what’s on your plate. Forget the foam fingers, here it's all about the brats and the OJ. It's like the Packers versus the Dolphins, but...
Continue Reading
Gildan's Channel Stuffing Allegations If July showers bring August flowers, then what do June allegations bring? A stock nosedive, if you’re Gildan Activewear. Investors woke up June 16, 2026, to a harrowing drop, with shares slipping nearly 19%. It's the kind of gut-punch that makes one wonder if summer vacation is over before it even starts. Jehoshaphat Research...
Continue Reading
AI Revolution in Marketing Content: CapCut Takes Lead It's like the old guard of marketing has hitched a ride on a rocket. In 2026, CapCut has stomped into the limelight with Better Business Advice giving them a nod for their prowess in AI-driven content creation. This isn't some passing trend; it's a seismic shift in how businesses craft their messages. CapCut ain't just...
Continue Reading
A Glimpse at Pathalys Pharma's Recent Win This is some groundbreaking stuff emerging from Pathalys Pharma. Their investigational drug, upacicalcet, has just clinched a significant victory in two crucial Phase 3 trials - PATH-1 and PATH-2 - aimed at treating Secondary Hyperparathyroidism (SHPT) in patients with end-stage kidney disease undergoing hemodialysis. With SHPT...
Continue Reading
Top 5 Most Recently Viewed Articles
Warren Buffett’s reign over Berkshire Hathaway (NYSE: BRK.A, NYSE: BRK.B) set a benchmark back in the day that still gets traders buzzing. You gotta love the Oracle of Omaha; he’s been schooling investors on the importance of finding those companies with real competitive moats—ya know, businesses that can fend off competition like a fortress. Back then, it was all...
Continue Reading
Valvoline Inc. CFO Transition and Retirement Announcement Valvoline Inc. (NYSE: VVV), known as a leader in preventive automotive maintenance, is navigating a transformative period with the upcoming retirement of its Chief Financial Officer, Mary Meixelsperger. This retirement marks the conclusion of an important chapter as Meixelsperger continues her role until a...
Continue Reading
Tenant Inc. Enhances Self-Storage Management with nodaFi Tenant Inc., a frontrunner in the self-storage technology space, has recently revealed an exciting partnership with nodaFi, focusing on optimizing operations across self-storage facilities. This collaboration introduces a robust integration that aims to improve efficiency and provide real-time insights, ensuring...
Continue Reading
Progress Update on the Android Transaction Dundee Corporation (TSX: DC.A) has provided a significant update on the ongoing sale of Android Industries. Since entering a binding Share Purchase Agreement, the parties involved have made substantial strides in addressing the preconditions needed for the deal to close. Most of these conditions have been fulfilled, yet, key...
Continue Reading
Exciting Developments in Dravet Syndrome Treatment An important collaboration between Biogen Inc. (NASDAQ: BIIB) and Stoke Therapeutics, Inc. (NASDAQ: STOK) has led to new findings regarding zorevunersen, an investigational antisense oligonucleotide. This promising treatment is currently being evaluated as a potential option for those affected by Dravet syndrome, a severe...
Continue Reading